Kiyatec Inc.’s Post

Glioblastoma multiforme (GBM) carries a grim prognosis with a <5% chance of 5-year survival following standard therapy. 3D Predict™ Glioma accurately predicted clinical response/nonresponse to TMZ in 85% (P=0.007) within 7 days of surgery and prior to treatment initiation. Now, you can test before you treat. Learn more: bit.ly/3SGc5L9 #Kiyatec #3DPredict #Glioma #BrainCancer #PrecisionMedicine #CancerTreatment

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics